

**DATE**

March 07, 2022

**SECTORS**

Healthcare

**DEAL LOCATIONS**



**DEAL TEAM**



**Wolfgang Kazmierowski**  
Managing Director

# DC Advisory advised c-LEcta on the sale of a majority stake to Kerry Group



## Background

- c-LEcta is a leading biotechnology innovation company based in Germany, specialising in precision fermentation, optimised bio-processing, and bio-transformation for the creation of high-value targeted enzymes and ingredients
- c-LEcta has established itself as a leading innovator in disruptive new sciences for the pharmaceutical market, with a strong pipeline of functional bioactives across food, beverage, and other consumer markets

## Process

- DC Advisory (DC) was engaged by the shareholders of c-LEcta to provide M&A advice due to DC's extensive experience in the biotechnology sector
- The DC deal team was led by Dr. Wolfgang Kazmierowski

## Outcome

- In March 2022, Kerry Group plc (Kerry), a leading global taste and nutrition company,

announced it had acquired 92% of the issued share capital of c-LEcta for EUR 137M, with management retaining the remaining 8%

- This strategically compelling combination will accelerate Kerry's innovation capabilities in enzyme engineering, fermentation, and bioprocess development
- Kerry's broad market reach across food and pharma markets, combined with its deep enzyme applications expertise and integrated ingredient technology design, will enable and accelerate the growth potential of c-LEcta's strong portfolio and technology capabilities
- This acquisition will further support Kerry's commitment to invest in the development of innovative sustainable technologies, which will be at the heart of future sustainable food and health systems